Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on GRAINGER PLC. We currently have 53 research reports from 1 professional analysts.
|16Feb17 15:40||RNS||Block Listing|
|13Feb17 14:32||RNS||Director/PDMR Shareholding|
|10Feb17 15:44||RNS||Holding(s) in Company|
|10Feb17 15:41||RNS||Director/PDMR Shareholding|
|10Feb17 15:35||RNS||Director/PDMR Shareholding|
|08Feb17 16:00||RNS||Result of AGM|
|08Feb17 10:35||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
N+1 Singer - Grainger - Positive start to FY17e, rental growth continues
08 Feb 17
Grainger has reported a solid start to the new financial year (4 months incl. Q1 and January) with continued rental growth and sales of vacant properties modestly ahead of HPI in the period. Positive progress has been made on PRS assets under development, with planning permission received on a 242 unit site in Leeds last week. Grainger highlights a positive impact from the Housing White Paper: the revised planning framework favouring affordable rent. We reiterate our BUY recommendation and 320p 12m Target Price. The shares continue to trade at a discount (15%) to NNNAV which ignores the value in the reversionary surplus and the opportunity to reinvest capital in yielding PRS.
N+1 Singer - Morning Song 08-02-2017
08 Feb 17
blur Group (BLUR LN) Trading update and first enterprise subscription | First Derivatives (FDP LN) Strategic investment partnership, target price increased | Grainger (GRI LN) Positive start to FY17e, rental growth continues | Victrex (VCT LN) Solid Q1, shine taken off by medical
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 01-12-2016
01 Dec 16
Blackstone/GSO Loan Financing (BGLF LN) CLO refinancing outlook | Clipper Logistics (CLG LN) Interims highlight further significant growth | Grainger (GRI LN) Final results in line, further progress on PRS investment pipeline | Vernalis (VER LN) AGM statement in line with expectations | WYG (WYG LN) Order book strength underpins FY expectations
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
Industry fundamentals remain positive
21 Feb 17
The Biotech Growth Trust (BIOG) is a specialist vehicle, aiming to generate long-term capital growth via investment in global biotech stocks. Following a particularly volatile period for the biotech industry, where concerns about drug pricing and investor risk aversion have weighed heavily on stock prices, the managers are hopeful that greater clarity regarding US healthcare policy will lead to continued improved performance of biotech stocks. Industry fundamentals remain attractive, including continued innovation and valuations are very supportive, which offers the potential for higher industry merger and acquisition activity.
Lloyds, Best Of The Banks
23 Feb 17
Lloyds Banking Group PLC (LLOY) reported a strong result for FY-16, which has allowed it to pay a special dividend, plus has encouraged the UK government to reduce its stake in the bank to below 5%. Lloyds’ acquisition of the MBNA credit card business is proceeding on track, with all key M&A metrics being well satisfied. The outlook for Lloyds’ capital base, its profitability and thus the dividend prospects have all improved. This encourages us to ascribe a Buy rating to the stock, with a target price of 80p per share, derived from a prospective Price / Book value of 1.3x and a P/E ratio of 13x which we think are justifiable ratios.
Middle Britain growth
21 Feb 17
The Company has achieved our 2017 estimate in 2016 with EBITDA of £2.2m, up 37% on 2015. We upgrade our estimates by 10% at the EBITDA level in 2017. If the shares traded even at the lower end of comparators, they would trade at 17p. We expect the share price to reach our upgraded 17p price target in the short term. Few companies enjoy the unique positioning which Lighthouse has to benefit from the assets of Middle Britain.
Marked confidence in profitability resilience
22 Feb 17
LBG posted a good set of results at the operating level. Management showed its confidence in the group’s ability to protect its indecent profitability levels over the next three years by recommending an increased ordinary dividend and the payment of a special dividend, and by setting a stable return on required equity objectives.
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume